Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gigacloud Technology Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Gigacloud Technology Inc trades at $33.62 (market cap $1.23B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 3.7× Gigacloud Technology Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | GCT | |
|---|---|---|
Market Cap | $4.49B | $1.23B |
Sector | Health | Technology |
52-Week High | $28.06 | $51.80 |
52-Week Low | $20.06 | $20.26 |
Enterprise Value | $3.69B | $1.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GigaCloud Technology (GCT) trades at $34.08, up 2.62% with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats, with Q1 2026 EPS of $1.04 exceeding expectations by 20%, and maintains healthy profitability with a 10.77% net margin. Recent news highlights inclusion in TIME's World's Growth Leaders 2026 list and positive analyst coverage, supporting investor confidence.
Outlook remains positive due to undervaluation (P/E 8.64), growth in European markets, and strategic expansions. Risks include potential fiduciary concerns flagged by shareholders and reliance on large parcel merchandise demand. Analyst consensus is 66.7% buy, with a $56 price target from Seeking Alpha on 2026-06-10 suggesting 64% upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
